Log In
BCIQ
Print this Print this
 

MM36 (formerly OPA-15406)

  Manage Alerts
Collapse Summary General Information
Company Otsuka Pharmaceutical Co. Ltd.
DescriptionPhosphodiesterase-4 (PDE-4) inhibitor
Molecular Target Phosphodiesterase-4 (PDE-4)
Mechanism of ActionPhosphodiesterase-4 (PDE-4) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationDermatitis
Indication DetailsTreat atopic dermatitis; Treat mild to moderate atopic dermatitis
Regulatory Designation
PartnerMedimetriks Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$22.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/09/2016

Undisclosed

$22.0M

Undisclosed

Get a free BioCentury trial today